EVENTS | VIEW CALENDAR
Affibody and Algeta begin cancer work
OSLO, Norway—Algeta ASA, a therapeutics company developing novel anticancer agents based on alpha-particle emitting radionuclides, and Affibody AB, which is building a pipeline of products based on tumor-targeting affinity molecules, have announced a research collaboration to develop novel targeted radiotherapeutics.
The collaboration will combine Algeta's TH-1 technology for attaching the alpha-particle emitting radionuclide thorium-227 to peptides and proteins, with Affibody molecules that specifically target tumor cells over-expressing HER2, such as breast cancer.
Targeted radiotherapeutics based on these leading-edge technologies will theoretically benefit from the proven high specificity and affinity of Affibody molecules for their targets nd the high-energy, short-range alpha particle radiation from thorium-227.
"The Affibody molecules ability to capture a specific tumor target in combination with our thorium-227 labeling technology offers great potential for developing a range of important new anticancer products with increased specificity and potency, and reduced side effects as a result of limited radiation to other tissues," says Dr Thomas Ramdahl, CEO of Algeta.
Dr Ulf Boberg, CEO of Stockholm-based Affibody, adds: "We are very pleased to collaborate with Algeta; it is regarded as a leader in the field of alpha-particle emitters and this collaboration fits well with Affibody's overall HER2-targeting therapy strategy. Algeta's nuclides are viewed as superior to gamma- and beta-radiating nuclides for tumor therapy and the combination with the Affibody molecules' exquisite target-finding capabilities make this collaboration really exciting."